Abstract
Currently, inhaled therapy using corticosteroids and/or bronchodilators is the major established treatment for chronic obstructive pulmonary disease (COPD). The topic to be covered in this chapter is the recently developed experimental approach using biologically active molecules secreted by the live genetically modified lactic acid bacteria (gmLAB). The strategy to use gmLAB as a therapeutic/delivering tool targeting disease-specific active molecules/cites is proceeding. The role of inflammation and oxidative stress in COPD development is a valid target point. Heme oxygenase (HO)-1 as an anti-inflammatory and antioxidative stress molecule has been examined to attenuate the lung function decline and inflammation in the murine model of COPD. Recently, HO-1-secreting gmLAB as a tool for targeting inflammatory diseases has been developed and examined in several disease models including COPD. When administered intratracheally, the gmLAB showed migration to the peripheral lung and overexpression of anti-inflammatory/oxidative HO-1 in both lung and serum, protecting the lung from COPD development.
Keywords
- chronic obstructive pulmonary disease
- inhaled therapy
- intratracheal therapy
- anti-inflammatory therapy
- antioxidative therapy
- genetically modified lactic acid bacteria
- heme oxygenase-1
1. Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by airway remodeling due to chronic inflammation and subsequent airflow limitation that should be considered most to be associated with chronic symptoms such as shortness of breath and dyspnea [1]. Inhaled bronchodilators of long-acting beta-2 agonist/muscarinic antagonist have been introduced to treat symptomatic COPD [2]. Recently, more focus on the inflammation as a background condition of COPD is growing attention to a therapeutic factor to be considered [3]. In this regard, an inhaled corticosteroid (ICS) has been involved in the standard therapy for moderate to severe COPD. However, using ICS raises the concern of an increased risk of pneumonia [4]. Thus, another class of anti-inflammatory therapeutic options would be awaited. In line with this concept, experimental anti-inflammatory therapy using heme oxygenase (HO)-1 administration or induction in murine lung disease model including emphysema has been reported with successful amelioration of disease progression [5, 6]. HO catalyzes the degradation of heme to biliverdin, carbon monoxide (CO), and iron [7]. Thus, the by-products of biliverdin and CO act as anti-inflammatory and antioxidative agents [8, 9]. The results showing that the serum levels of HO-1 in patients with COPD having significantly lower compared to those in healthy adults could support the benefits of HO-1 adminitration/induction in the lungs of COPD [10]. A recent report indicates that the HO-1 could regulate lung inflammatory/oxidtative stress status by modulating mitogen-activated protein kinase (MAPK) pathway especially for extracellular signal-regulated kinase (ERK) [11].
There are several ways of induction and/or upregulation of HO-1 in the lungs by 1) chemical induction using hemin or CoPP [10, 12] and 2) local/systemic administration of recombinant HO-1 [5, 6, 13].
Especially, the use of generally recognized as safe (GRAS) materials such as lactic acid bacteria (LAB) for producing/delivering the therapeutics for human diseases such as inflammatory bowel disease and colorectal cancer has been gaining growing attention [14, 15, 16, 17]. In addition, exploring the conceptional use of GRAS materials for lung diseases has been planned and tried for an experimental COPD model [13, 18].
This chapter summarizes the detailed experimental approach of the intratracheal administration of GRAS microbes for producing/delivering therapeutics in the COPD model.
2. Usage of lactic acid bacteria for intratracheal administration
2.1 Construction of genetically modified lactic acid bacteria (LAB)
There have been various LABs constructed for specific target therapy and/or monitoring the LAB dynamics after administration in the animal/human body. Lactococcus (L.) lactis NZ9000 for nisin regulated target gene expression system (MoBiTec, Goettingen, Germany) was used for these purposes. The genetically modified
The GFP-expressing
2.2 Airway migration of nasally administered L. lactis
GFP-expressing
As shown in Figure 3, visualized GFP signal was time-dependently moved from the central lesion to the peripheral lesion of the lungs. Finally, the GFP signal was cleared from the lungs 96 hr after administration. Notably, at the same time of 96 hr, there was still an apparent GFP signal in the trachea, indicating 1) the high affinity of
2.3 Systemic effect of nasally administered L. lactis
Potential systemic influences after administering
2.4 Local effects of nasally administered L. lactis
Another concern after nasally administering
3. Usage of lactic acid bacteria for COPD model
3.1 Construction of genetically modified L. lactis secreting anti-inflammatory/ antioxidative stress protein HO-1
To explore the anti-inflammatory therapeutic option other than corticosteroids in COPD, HO-1 was focused on because of its low serum level shown in patients with COPD [10]. The newly constructed HO-1 secreting
3.2 HO-1 production in the lungs after nasally administering HO-1 L. lactis
HO-1 secreting
3.3 Effect of nasally administered HO-1 secreting L. lactis in murine emphysema model
HO-1-secreting
On day 21, after PPE instillation, the mice developing pulmonary emphysema were evaluated by pulmonary function test using the flexiVent system (emka TECHNOLOGIES Japan).
3.3.1 Systemic effect of nasally administered HO-1 secreting L. lactis
Mice pretreated with 1.0 × 109 of HO-1
3.3.2 Local effect of nasally administered HO-1 secreting L. lactis
In human clinical trials, the efficacy of candidate drugs for COPD should be primarily assessed by inhibiting lung function deterioration [20]. Therefore, in vivo lung function measurements of mice receiving with or without HO-1
4. Conclusions
This chapter summarizes the potential therapeutics of gmLAB and its application for lung diseases, including COPD. LAB has been widely used as probiotics for health, and to maximize its beneficial effects, gmLAB has been developed. Among several gmLABs, the use of
Acknowledgments
Authors thank Drs. Kentaro Nakashima and Kentaro Yumoto (Yokohama City University, Japan) and Drs. Suguru Shigemori and Fu Namai (Shinshu University, Japan) for their significant contribution to the project. The project was funded by the Japan Society for the Promotion of Science (JSPS) KAKENHI, grant numbers JP15K09224, JP18K19935, JP19KK0208, and JP22K08578 to Takashi Sato.
References
- 1.
James AL, Wenzel S. Clinical relevance of airway remodelling in airway diseases. The European Respiratory Journal. 2007; 30 (1):134-155. DOI: 10.1183/09031936.00146905 - 2.
Page C, Cazzola M. Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease. The European Respiratory Journal. 2014; 44 (2):475-482. DOI: 10.1183/09031936.00003814 - 3.
King PT. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clinical and Translational Medicine. 2015; 4 (1):68. DOI: 10.1186/s40169-015-0068-z - 4.
Wang CY, Lai CC, Yang WC, Lin CC, Chen L, Wang HC, et al. The association between inhaled corticosteroid and pneumonia in COPD patients: The improvement of patients’ life quality with COPD in Taiwan (IMPACT) study. International Journal of Chronic Obstructive Pulmonary Disease. 2016; 11 :2775-2783. DOI: 10.2147/COPD.S116750 - 5.
Otterbein LE, Kolls JK, Mantell LL, Cook JL, Alam J, Choi AM. Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury. The Journal of Clinical Investigation. 1999; 103 (7):1047-1054. DOI: 10.1172/JCI5342 - 6.
Shinohara T, Kaneko T, Nagashima Y, Ueda A, Tagawa A, Ishigatsubo Y. Adenovirus-mediated transfer and overexpression of heme oxygenase 1 cDNA in lungs attenuates elastase-induced pulmonary emphysema in mice. Human Gene Therapy. 2005; 16 (3):318-327. DOI: 10.1089/hum.2005.16.318 - 7.
Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proceedings of the National Academy of Sciences of the United States of America. 1968; 61 (2):748-755. DOI: 10.1073/pnas.61.2.748 - 8.
Otterbein LE, Bach FH, Alam J, Soares M, Tao Lu H, Wysk M, et al. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nature Medicine. 2000; 6 (4):422-428. DOI: 10.1038/74680 - 9.
Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science. 1987; 235 (4792):1043-1046. DOI: 10.1126/science.3029864 - 10.
Sato T, Takeno M, Honma K, Yamauchi H, Saito Y, Sasaki T, et al. Heme oxygenase-1, a potential biomarker of chronic silicosis, attenuates silica-induced lung injury. American Journal of Respiratory and Critical Care Medicine. 2006; 174 (8):906-914. DOI: 10.1164/rccm.200508-1237OC - 11.
Nakashima K, Sato T, Shigemori S, Shimosato T, Shinkai M, Kaneko T. Regulatory role of heme oxygenase-1 in silica-induced lung injury. Respiratory Research. 2018; 19 (1):144. DOI: 10.1186/s12931-018-0852-6 - 12.
Minamoto K, Harada H, Lama VN, Fedarau MA, Pinsky DJ. Reciprocal regulation of airway rejection by the inducible gas-forming enzymes heme oxygenase and nitric oxide synthase. The Journal of Experimental Medicine. 2005; 202 (2):283-294. DOI: 10.1084/jem.20050377 - 13.
Yumoto K, Sato T, Nakashima K, Namai F, Shigemori S, Shimosato T, et al. Nasally administered lactococcus lactis secreting heme oxygenase-1 attenuates murine emphysema. Antioxidants (Basel). 2020; 9 (11):283-294. DOI: 10.3390/antiox9111049 - 14.
Ciacma K, Wieckiewicz J, Kedracka-Krok S, Kurtyka M, Stec M, Siedlar M, et al. Secretion of tumoricidal human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by recombinant Lactococcus lactis: Optimization of in vitro synthesis conditions. Microbial Cell Factories. 2018; 17 (1):177. DOI: 10.1186/s12934-018-1028-2 - 15.
Namai F, Shigemori S, Ogita T, Sato T, Shimosato T. Microbial therapeutics for acute colitis based on genetically modified Lactococcus lactis hypersecreting IL-1Ra in mice. Experimental & Molecular Medicine. 2020; 52 (9):1627-1636. DOI: 10.1038/s12276-020-00507-5 - 16.
Shigemori S, Shimosato T. Applications of genetically modified immunobiotics with high immunoregulatory capacity for treatment of inflammatory bowel diseases. Frontiers in Immunology. 2017; 8 :22. DOI: 10.3389/fimmu.2017.00022 - 17.
Shigemori S, Watanabe T, Kudoh K, Ihara M, Nigar S, Yamamoto Y, et al. Oral delivery of Lactococcus lactis that secretes bioactive heme oxygenase-1 alleviates development of acute colitis in mice. Microbial Cell Factories. 2015; 14 :189. DOI: 10.1186/s12934-015-0378-2 - 18.
Sato T, Shimosato T. Development of a New Treatment Modality for Lung Diseases That Uses Innovative Fine Droplet Drying (fdd) Technology Offering Inhalable Nano/microparticles-incorporated Therapeutic Agents. New York: Science Impact Ltd; 2019. DOI: 10.21820/23987073.2019.3.56 - 19.
Shigemori S, Namai F, Yamamoto Y, Nigar S, Sato T, Ogita T, et al. Genetically modified Lactococcus lactis producing a green fluorescent protein-bovine lactoferrin fusion protein suppresses proinflammatory cytokine expression in lipopolysaccharide-stimulated RAW 264.7 cells. Journal of Dairy Science. 2017; 100 (9):7007-7015. DOI: 10.3168/jds.2017-12872 - 20.
Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: From lung function to biomarkers. The European Respiratory Journal. 2008; 31 (2):416-469. DOI: 10.1183/09031936.00099306 - 21.
Vanoirbeek JA, Rinaldi M, De Vooght V, Haenen S, Bobic S, Gayan-Ramirez G, et al. Noninvasive and invasive pulmonary function in mouse models of obstructive and restrictive respiratory diseases. American Journal of Respiratory Cell and Molecular Biology. 2010; 42 (1):96-104. DOI: 10.1165/rcmb.2008-0487OC